CTRI/2020/12/029776招募中未知
Optimizing place of treatment for young infants presenting with any low mortality risk sign of possible serious bacterial infection-Study 1 - PSBI RCT 1
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All young infants < 2months days old, living in a geographic area where follow-up for 14 days can be accomplished presenting to outpatient clinics or emergency rooms of participating hospitals will considered for inclusion in this study if they have ONLY one of the following low-risk signs of PSBI:
- •1. Body temperature >=38°C, or
- •2. Severe chest indrawing, or
- •3. Fast breathing ( <7 days old infants).
排除标准
- •1. Weight <2kg at the time of presentation (if age at screening is less than 10 days) or weight for age <-3z, or
- •2. Signs of critical illness (no movement at all, unable to feed at all, convulsions), or
- •3.Signs of CSI associated with a high risk of mortality (stopped feeding well, movement only on stimulation, low body temperature < 35.5oC or two or more of the six signs of CSI), or
- •4. Any sign suggestive of another serious illness/condition, such as major congenital malformations, severe jaundice, conditions requiring major surgery, meningitis, bone or joint infection, severe dehydration, etc., or
- •5. Appearance of low-mortality risk signs in first 24 hours of life , or
- •6. Hospitalized for any illness in the previous 2 weeks, or
- •7. Prior use of injectable antibiotics for the same illness, or
- •8. Previously included in this study or currently included in any other study
研究者
相似试验
已完成
不适用
Optimal place of treatment for young infants aged less than 2 months with any one low-mortality-risk sign of possible serious bacterial infectioTreatment of low-mortality-risk signs of possible serious bacterial infection in young infantsInfections and InfestationsPossible serious bacterial infectionISRCTN44033252World Health Organization7,002
进行中（未招募）
1 期
Traitement précoce de patients pédiatriques présentant un syndrome hémolytique et urémique typique par l’anticorps monoclonal anti-C5 eculizumab : essai thérapeutique prospectif randomisé contrôlé contre placebo de phase IIIHemolytic and uremic syndromeMedDRA version: 17.0 Level: LLT Classification code 10042814 Term: Syndrome hemolytic uremic System Organ Class: 100000004851EUCTR2014-001169-28-FRCentre Hospitalier de Toulouse100
招募中
不适用
Optimizing duration of hospitalization for young infants with sepsisCTRI/2020/12/029623Centre for Health Research and Development Society for Applied Studies
已完成
不适用
Improving the care of ventilated preterm babies by weighing them within the incubatorAssessing the accuracy of integral incubator scales in weighing ventilated infantsNeonatal DiseasesVentilation of neonatesISRCTN58085619Royal Salford NHS Trust30
已完成
不适用
Improving SCBU Care for Preterm BabiesPreterm InfantPreterm BirthNCT03512093University of Oxford36